Immunohistochemical Analysis of the Effect of Dienogest on Ovarian Endometriotic Cysts

Nguyễn Thị Thanh Thủy, Thuy Thi Nguyen, Toru Hachisuga, Rie Urabe, Taeko Ueda, Tomoko Kurita, Seiji Kagami, Toshinori Kawagoe, Masanori Hisaoka
Journal of UOEH · 2016 · vol. 38(4) , pp. 271–278 · doi:10.7888/juoeh.38.271 · PMID:27980309 · W2564815493
article OA: bronze CC0 ⤵ 2 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Dienogest treatment reduced cell proliferation in ovarian endometriotic cysts, but did not significantly alter estrogen receptor-α or progesterone receptor A expression.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

The study evaluated the effect of dienogest on ovarian endometriotic cysts using immunohistochemistry in cyst specimens from 12 treated patients and 20 hormone-naive controls, assessing ER-α, progesterone receptor A (PRA), and Ki-67 proliferation indices in epithelial and stromal cells. Dienogest significantly reduced the cell proliferation index in both epithelial and stromal cells compared with controls, while ER-α and PRA expression showed no significant differences between treated and untreated cysts; ER-α and PRA were described as low in epithelial cells but well preserved in stromal cells regardless of treatment. In controls, Ki-67, ER-α, and PRA did not differ between proliferative and secretory phases. The authors note that reduced proliferation without changes in hormonal receptor expression may not support a direct progestational effect of dienogest on ovarian endometriotic cysts. This paper is centrally about endometriosis— it directly tests dienogest’s effects on biomarkers in ovarian endometriotic cyst tissue.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Dienogest is a novel progestin with potent oral progestational activity that inhibits the clinical symptoms of endometriosis. We herein evaluated the effect of dienogest on ovarian endometriotic cysts via immunohistochemistry. Ovarian endometriotic cyst specimens were collected from 12 patients treated with dienogest and 20 patients not treated with hormones (controls). The expression of estrogen receptor (ER)-α, progesterone receptor A (PRA), and Ki-67 was studied by immunohistochemistry. As compared with the controls, the cell proliferation index was significantly reduced in both epithelial and stromal cells of the endometriotic cysts following the use of dienogest (P = 0.022 and P = 0.004, respectively). However, there was no significant difference between endometriotic cysts with and without the use of dienogest in the expressions of ER-α and PRA in the epithelial and stromal cells. Irrespective of the use of dienogest, the expression levels of ER-α and PRA in the epithelial cells were low (median: 32% and 8%, respectively). Conversely, the expression levels of ER-α and PRA in the stromal cells were well preserved (median: 68% and 92%, respectively). In the controls, there was no significant difference between endometriotic cysts in the expression levels of Ki-67, ER-α and PRA in epithelial and stromal cells during the proliferative and secretory phases. The finding of a reduction in the cell proliferation index by the use of dienogest with no change in the expressions of hormonal receptors may not support the direct progestational effect of dienogest on ovarian endometriotic cysts.
Full text 1,868 characters · extracted from oa-doi-fallback · click to expand
Immunohistochemical Analysis of the Effect of Dienogest on Ovarian Endometriotic Cysts 2016 Volume 38 Issue 4 Pages 271-278 Details Abstract Dienogest is a novel progestin with potent oral progestational activity that inhibits the clinical symptoms of endometriosis. We herein evaluated the effect of dienogest on ovarian endometriotic cysts via immunohistochemistry. Ovarian endometriotic cyst specimens were collected from 12 patients treated with dienogest and 20 patients not treated with hormones (controls). The expression of estrogen receptor (ER)-α, progesterone receptor A (PRA), and Ki-67 was studied by immunohistochemistry. As compared with the controls, the cell proliferation index was significantly reduced in both epithelial and stromal cells of the endometriotic cysts following the use of dienogest (P = 0.022 and P = 0.004, respectively). However, there was no significant difference between endometriotic cysts with and without the use of dienogest in the expressions of ER-α and PRA in the epithelial and stromal cells. Irrespective of the use of dienogest, the expression levels of ER-α and PRA in the epithelial cells were low (median: 32% and 8%, respectively). Conversely, the expression levels of ER-α and PRA in the stromal cells were well preserved (median: 68% and 92%, respectively). In the controls, there was no significant difference between endometriotic cysts in the expression levels of Ki-67, ER-α and PRA in epithelial and stromal cells during the proliferative and secretory phases. The finding of a reduction in the cell proliferation index by the use of dienogest with no change in the expressions of hormonal receptors may not support the direct progestational effect of dienogest on ovarian endometriotic cysts. © 2016 The University of Occupational and Environmental Health, Japan Favorites & Alerts Recently viewed articles

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Cysts Cysts Endometriosis Endometriosis Hormone Antagonists Nandrolone Adult Cysts Endometriosis Endometriosis Female Hormone Antagonists Humans Immunohistochemistry Nandrolone Nandrolone Treatment Outcome

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (17)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-12T06:13:51.797165+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:43.714878+00:00
License: CC0 · commercial use OK